Clinical Data Implements Luminex xMAP Solution, Expanding Breadth of Its Genotyping Services.

The Luminex([R]) xMAP([R]) system to enhance Cogenics' clinical and agricultural genotyping franchises

Clinical Data awarded Luminex Partner status

NEWTON, Mass. -- Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics[TM] division, a provider of comprehensive pharmacogenomics and molecular biology services, has implemented a Luminex xMAP([R]) multiplexing system to expand its genotyping service offerings and advance its clinical and agricultural genotyping franchises.

Cogenics is introducing services based on the Luminex xMAP platform at its GLP facility in Morrisville, NC. The new Luminex system is ideally suited to address the growing demand for robust, high throughput multiplexed genotyping studies for research applications and clinical trials services and will advance Cogenics' clinical and agricultural genotyping franchises. As a Luminex Partner, Cogenics will offer custom genotyping assays and commercially available xMAP based kits from third party companies.

Robert Bondaryk, Ph.D., Senior Vice President and General Manager of Cogenics, commented, "We are excited to offer the Luminex platform and its benefits to our growing client base. We feel that the addition of this technology allows Cogenics to continue to enhance its service offerings to pharmaceutical and biotech companies and academic clients, by providing a versatile, new age genomic platform that can be utilized for both research and regulated studies."

Luminex Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. Luminex's xMAP system is an open-architecture, multi-analyte profiling technology that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.

Bondaryk continued, "Cogenics has developed a portfolio of over one hundred genomics-based services to support the growing needs of its commercially driven client base. Over the last several years, Cogenics has positioned itself for rapid growth by expanding its capacity for these services through the acquisition of new instrumentation, automation, improved processes, and capacity utilization. The addition of the Luminex multiplexing platform continues this trend and strengthens Cogenics' position as a premier provider of pharmacogenomic and molecular biology services."

About Clinical Data, Inc.

Clinical Data, Inc. is a global biotechnology company unlocking the potential of molecular discovery, from targeted science to better healthcare. Its PGxHealth division focuses on genetic test and biomarker development to help predict drug safety and efficacy, thereby reducing health care costs and improving clinical outcomes. Its Cogenics division provides molecular and pharmacogenomics services to both research and regulated environments. Its Vital Diagnostics division offers in vitro diagnostics solutions for the clinical laboratory. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists, and health plans worldwide. For more information, visit www.clda.com.

About Cogenics

Cogenics offers more than 15 years of experience as a trusted provider of the broadest range of pharmacogenomics and molecular biology services available globally. Cogenics provides integrated services for nucleic acid extraction, genotyping, sequencing, QPCR, and gene expression, as well as serving as a biorepository, for both research and regulated environments: GLP, cGMP and CLIA. Cogenics combines operations from the acquisitions of Genaissance Pharmaceuticals, Lark Technologies (US & UK), Icoria, and Genome Express (France). Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. Visit the company's website at www.cognenics.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains certain forward-looking information about Clinical Data that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to statements regarding: our ability to successfully integrate the operations, business, technology and intellectual property obtained in our acquisitions; our ability to obtain regulatory approval for, and successfully introduce our products and services; our ability to expand our long-term business opportunities; our ability to maintain normal terms with our customers and partners; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether our sequencing services will gain wide acceptance in the market; our ability to achieve the expected synergies and operating efficiencies from all of our acquisitions; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for pharmacogenetic products and services; general economic downturns; and other risks contained in our various SEC reports and filings, including but not limited to our Quarterly Report on Form 10-Q for the quarter ended December 31, 2006, and our subsequent Current Reports on Form 8-K filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.